Buruli ulcer
Buruli ulcer (BU) is a chronic debilitating skin disease caused by Mycobacterium ulcerans. It has been reported in 33 countries in Africa, the Americas, Asia and the Western Pacific. The exact mode of transmission of M. ulcerans is still unknown.
Buruli ulcer often starts as a painless swelling (nodule), a large painless area of induration (plaque) or a diffuse painless swelling of the legs, arms or face (oedema). Because of the wide range of presentations, clinical diagnosis can be challenging. Effective antibiotic treatment using a combination of rifampicin and clarithromycin is available.
Early accurate diagnosis and treatment is vital in preventing the severity of the disease with consequent disability. The development of rapid diagnostic tools for use at primary health care level is a priority for national control programmes.
The World Health Organization (WHO) is seeking feedback on the TPP from experts in the industry, product developers, the scientific community, NTD programme personnel and clinicians currently involved in the management and control of Buruli ulcer.
Details of the TPPs may be found in the linked document.
Proposed revisions arising from the public consultation will be considered by the TPP working group before it is finalized. The final TPPs will be used for the development of diagnostics to improve decisions leading to the improved control and treatment of Buruli ulcer.